BRIEF—India's Lupin names new president of US Specialty business

India drugmaker Lupin Limited has announced the appointment of Jon Stelzmiller as the president of its US Specialty business.
Mr Stelzmiller brings to Lupin over 30 years of experience in the specialty segment and will be replacing Nicholas Hart.

Mr Stelzmiller has a proven track record of building high-performing teams and launching 18 major brands across 14 different therapeutic areas including women’s health, oncology and anti-infectives.

Most recently, he was senior vice president and general manager — Women’s Healthcare at Bayer, where he helped build and lead a billion-dollar women’s health business in the USA.

Prior to Bayer, Mr Stelzmiller spent 12 years at Pfizer in roles of increasing commercial responsibilities in Specialty areas including Institutional sales and market access.

Commenting on the appointment, Lupin chief executive Vinita Gupta said: “Jon’s extensive experience in the pharmaceutical industry, particularly in women’s health segment in the US, will be a great asset for Lupin as we build our specialty business, including Solosec [secnidazole]. We are delighted to welcome Jon on board.”